Valuation: Compass Therapeutics, Inc.

Market Cap 344M 298M 278M 255M 482M 32.81B 490M 3.27B 1.28B 16.34B 1.29B 1.26B 54.14B P/E 2026 *
-4.38x
P/E 2027 * -4.11x
Enterprise Value 194M 168M 157M 144M 272M 18.5B 276M 1.84B 724M 9.21B 728M 712M 30.53B EV / Sales 2026 *
-94.3x
EV / Sales 2027 * 8.39x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
1 day-1.55%
1 week-7.73%
1 month-12.79%
3 months+7.91%
6 months-70.16%
Current year-64.43%
1 week 1.86
Extreme 1.86
2.22
1 month 1.86
Extreme 1.86
2.36
Current year 1.61
Extreme 1.61
6.88
1 year 1.61
Extreme 1.61
6.88
3 years 0.76
Extreme 0.765
6.88
5 years 0.76
Extreme 0.765
6.88
10 years 0.76
Extreme 0.765
11
Manager TitleAgeSince
Chief Executive Officer 65 28/05/2024
Director of Finance/CFO 54 09/12/2024
Chief Tech/Sci/R&D Officer 50 01/01/2026
Director TitleAgeSince
Director/Board Member 65 01/01/2014
Director/Board Member 64 01/01/2015
Chairman 61 01/01/2015
Date Insider Type Main position Quantity % Market Cap.
2/8/26 A Tax

Chief Executive Officer

36,687 0.0206%
1/9/26 A Tax

Chief Executive Officer

46,777 0.0263%
1/2/26 A Free

Chairman

90,000 0.0506%
Change 5-day change 1-year change 3-year change Capi.($)
-1.55%-7.73%-35.69%-33.45% 344M
+2.35%+2.74%+33.41%+79.20% 56.54B
-0.21%-7.38%+25.34%+63.02% 53.6B
-2.44%+1.40%-15.74%-16.80% 22.91B
-2.85%-7.78%-8.09%+346.36% 21.37B
+2.49%-0.92%+20.31%-12.15% 20.27B
+0.79%-1.06%+29.29%-33.32% 17.56B
+0.58%-5.88%+16.30%+540.37% 14.75B
-5.25%-4.23%+46.41%+169.05% 13.33B
+3.41%-6.61%+163.08%+280.43% 13.53B
Average -0.27%-4.19%+27.46%+138.27% 23.42B
Weighted average by Cap. +0.23%-2.97%+28.58%+119.75%

Financials

2026 *2027 *
Net sales -2.06M -1.78M -1.66M -1.53M -2.88M -196M -2.93M -19.56M -7.68M -97.73M -7.73M -7.56M -324M 25.27M 21.92M 20.4M 18.75M 35.42M 2.41B 35.99M 240M 94.35M 1.2B 94.89M 92.81M 3.98B
Net income -82.44M -71.51M -66.56M -61.16M -116M -7.86B -117M -784M -308M -3.92B -310M -303M -12.98B -89.57M -77.7M -72.32M -66.44M -126M -8.54B -128M -852M -334M -4.26B -336M -329M -14.1B
Net Debt -150M -130M -121M -111M -210M -14.31B -214M -1.43B -560M -7.13B -563M -551M -23.61B -132M -115M -107M -97.92M -185M -12.59B -188M -1.26B -493M -6.27B -496M -485M -20.78B
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
39
Date Price Change Volume
31/07/26 $1.910 -1.55% 2,640,537
30/07/26 $1.940 -.--% 1,913,204
29/07/26 $1.940 -4.90% 3,176,181
28/07/26 $2.040 -1.92% 3,147,926
27/07/26 $2.080 +0.48% 3,401,640
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
1.910USD
Average target price
8.500USD
Spread / Average Target
+345.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPX Stock